Evaluation of vaccine allergy safety track program to assess potential COVID-19 vaccine allergy: a cost-effectiveness analysis
Asian Pacific Journal of Allergy and Immunology · 2025
DOI: 10.12932/ap-270524-1864 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Pacific Journal of Allergy and Immunology, 2025. Verfasst von Xuechen Xiong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Ministry of Health and Welfare Pingtung Hospital, Pingtung, Taiwan. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, Drug Hypersensitivity.
Abstract (Originalsprache)
BACKGROUND: Concerns about new COVID-19 vaccines played a key role in vaccine hesitancy and hampered population uptake. Hong Kong initiated a Vaccine Allergy Safety Track (VAS-Track) program to assess potential COVID-19 vaccine-associated allergies. A 'Hub-and-Spoke' model of predominately non-specialists supported by the allergist hub was established to meet overwhelming demand despite limited specialists. OBJECTIVE: To assess the cost-effectiveness of VAS-Track as a pre- and post-vaccination assessment service for individuals potentially at high risk of COVID-19 vaccine-related allergy. METHODS: An individual-level decision-analytical model was constructed using data from VAS-Track participants supplemented by published estimates. Analyses were from a health service provider perspective over 12 months. We calculated the incremental cost-effectiveness ratio (ICER) to estimate the cost per quality-adjusted life years (QALYs) gained. Willingness-to-pay threshold was based on local GDP per capita (US$ 49,590). Sensitivity analyses examined robustness of findings. RESULTS: Cost-effectiveness varied widely across age groups. VAS-Track was cost-saving for older adults (dominant strategy for age ≥ 50) compared with standard practice across a range of sensitivity analyses. VAS-Track was not cost-effective for younger groups (age 18-49: ICER: US$ 410,914/QALY for pre-vaccination and US$ 213,786/QALY for post-vaccination assessments). Infection rate, cost of treating severe infection, and vaccination rate were most influential on cost-effectiveness estimates. CONCLUSION: VAS-Track was cost-effective both as a pre- and post-vaccination assessment service for adults over 50. The 'Hub-and-Spoke' model using non-specialists with limited allergy specialist resources to provide vaccine allergy assessment services would provide high economic value compared with usual care for adults aged 50 and over.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Ministry of Health and Welfare Pingtung Hospital, Pingtung, Taiwan.
- Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong.
- Division of Clinical Immunology, Department of Pathology, Queen Mary Hospital, Hong Kong.
- Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
- HKU Business School, The University of Hong Kong, Hong Kong.
Zitieren
APA
Xiong, X., Huo, Z., Chiang, V., Ye, J., Hong, Y. D., Yi, X., Ng, C. S., Li, P. H., & Quan, J. (2025). Evaluation of vaccine allergy safety track program to assess potential COVID-19 vaccine allergy: a cost-effectiveness analysis. Asian Pacific Journal of Allergy and Immunology. https://doi.org/10.12932/ap-270524-1864
Vancouver
Xiong X, Huo Z, Chiang V, Ye J, Hong YD, Yi X, et al. Evaluation of vaccine allergy safety track program to assess potential COVID-19 vaccine allergy: a cost-effectiveness analysis. Asian Pacific Journal of Allergy and Immunology. 2025. doi:10.12932/ap-270524-1864
BibTeX
@article{Xiong2025,
author = {Xiong, Xuechen and Huo, Zhaohua and Chiang, Valerie and Ye, Jiaxi and Hong, Yuh Dong and Yi, Xingnan and Ng, Carmen S and Li, Philip H and Quan, Jianchao},
title = {Evaluation of vaccine allergy safety track program to assess potential COVID-19 vaccine allergy: a cost-effectiveness analysis},
journal = {Asian Pacific Journal of Allergy and Immunology},
year = {2025},
doi = {10.12932/ap-270524-1864}
}
EUVIMED